BMS-986504 in Recurrent Glioblastoma
About the Recurrent Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1 clinical trial to evaluate BMS-986504, an experimental drug intended to encourage anti-tumor activity in recurrent glioblastoma with MTAP deletion.
This Phase 0/1 clinical trial will assess the drug’s ability to cross the blood-brain barrier in patients with MTAP-deleted recurrent glioblastoma, and measure tumor response to the drug.
The main goal of this study is to evaluate how much BMS-986504 accumulates in the tumor tissue of participants. Patients who demonstrate adequate drug penetration may be eligible for continued treatment within the trial’s expansion phase.
Glioblastoma Trial Details
Recruiting
BMS-986504
Recurrent Glioblastoma
You may be eligible if:
- You are 18 years or older
- You have a histologically diagnosed glioblastoma, and a biopsy confirmed a recurrence.
- You received previous first-line treatment with standard-of-care radiotherapy and temozolomide.
- You have sufficient archived or biopsy tissue for testing MTAP deletion.
How it works
Once enrolled, a patient receives a very small exposure to the experimental therapy days before a planned operation to remove their tumor.
This exposure is enough that when we remove the tumor, our team of experts can ask an important question: Did the treatment penetrate the tumor?
If the answer is yes, the patient may move forward with receiving a full dose of the treatment in an expansion arm of the trial.
Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.
Am I eligible?
Submit a free trial screening request today to learn if you may qualify for any of our studies.
